The Value of MicroRNA-21 As a Biomarker for the Prognosis of Lung Cancer: A Protocol for Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Sep 3

PMID 32871993

Citations 3

Authors

Wei Zhang

Lin Wei

Rong Luo

Hui Liu

Jing Chen

Affiliations

Soon will be listed here.

Abstract

Backgroud: More and more studies are investigating the influence of the expression of MicroRNA-21 (miRNA-21) on prognosis and clinical significance in patients with lung cancer, but the results are contradictory and uncertain. A meta-analysis was conducted with controversial data to accurately assess the issue.

Methods: A detailed search of relevant research in Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, Web of Science and other databases. Two reviewers independently conducted data extraction and literature quality evaluation. Odd ratio and its 95% confidence intervals were used to evaluate the relationship between miRNA-21 and clinicopathological characteristics of lung cancer patients. Hazard ratios and its 95% confidence intervals To assess the prognostic effect of miRNA-21 on overall survival and disease-free survival. Meta analysis was performed using RevMan 5.3 and Stata 14.0 software.

Results: This study will provide a high-quality evidence-based medical evidence of the correlations between miRNA-21 expression and overall survival, disease-free survival and clinicopathological features.

Conclusion: The study will provide updated evidence to evaluate whether the expression of miRNA-21 is in association with poor prognosis in patients with lung cancer.

Ethics And Dissemination: The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not available. The results may be published in a peer- reviewed journal or disseminated in relevant conferences.

Osf Registration Number: DOI 10.17605/OSF.IO/X3MD6.

Citing Articles

The physiological functions and therapeutic potential of exosomes during the development and treatment of polycystic ovary syndrome.

Zhang Z, Shi C, Wang Z Front Physiol. 2023; 14:1279469.

PMID: 38028777 PMC: 10657906. DOI: 10.3389/fphys.2023.1279469.

Prognostic value of microRNA-21 in epithelial ovarian carcinoma: A protocol for systematic review and meta analysis.

Ji K, Wang X, Zhang A, Wen H Medicine (Baltimore). 2020; 99(52):e23849.

PMID: 33350775 PMC: 7769334. DOI: 10.1097/MD.0000000000023849.

The value of microRNA-203 as a biomarker for the prognosis of esophageal cancer: A protocol for systematic review and meta-analysis.

Wang S, Yu P, Meng Z, Feng L Medicine (Baltimore). 2020; 99(50):e23599.

PMID: 33327325 PMC: 7738148. DOI: 10.1097/MD.0000000000023599.

References

Ma Y, Xia H, Liu Y, Li M . Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. Biomed Res Int. 2014; 2014:617868. PMC: 3997135. DOI: 10.1155/2014/617868. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W . High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 2012; 49(3):604-15. DOI: 10.1016/j.ejca.2012.09.031. View

Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L . Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett. 2017; 13(2):669-676. PMC: 5351202. DOI: 10.3892/ol.2016.5462. View

Liu Z, Wang H, Liu J, Wang Z . MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 2012; 372(1-2):35-45. DOI: 10.1007/s11010-012-1443-3. View

Cheng C, Bahal R, Babar I, Pincus Z, Barrera F, Liu C . MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2014; 518(7537):107-10. PMC: 4367962. DOI: 10.1038/nature13905. View

Wang L, Yu C, Liu Y, Wang J, Li C, Wang Q . Lung Cancer Mortality Trends in China from 1988 to 2013: New Challenges and Opportunities for the Government. Int J Environ Res Public Health. 2016; 13(11). PMC: 5129262. DOI: 10.3390/ijerph13111052. View

Seder C, Kubasiak J, Pithadia R, Basu S, Fhied C, Tarhoni I . Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015; 100(2):429-36. DOI: 10.1016/j.athoracsur.2015.04.018. View

Gallach S, Jantus-Lewintre E, Calabuig-Farinas S, Montaner D, Alonso S, Sirera R . MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value. Oncotarget. 2017; 8(34):56143-56157. PMC: 5593550. DOI: 10.18632/oncotarget.18603. View

10.

Chen Z, Huang L, Zhu B . Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer. Dis Markers. 2019; 2018:9845123. PMC: 6311751. DOI: 10.1155/2018/9845123. View

11.

Yang J, Li B, Lu H, Chen Y, Lu C, Zhu R . Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2014; 36(4):3035-42. DOI: 10.1007/s13277-014-2938-1. View

12.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

13.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

14.

Liu X, Zhu W, Huang Y, Ma L, Zhou S, Wang Y . High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol. 2011; 29(2):618-26. DOI: 10.1007/s12032-011-9923-y. View

15.

Capodanno A, Boldrini L, Proietti A, Ali G, Pelliccioni S, Niccoli C . Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol. 2013; 43(3):765-74. DOI: 10.3892/ijo.2013.2003. View

16.

Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis W . Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer. 2008; 64(2):148-54. PMC: 2849638. DOI: 10.1016/j.lungcan.2008.08.009. View

17.

Markou A, Tsaroucha E, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou E . Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008; 54(10):1696-704. DOI: 10.1373/clinchem.2007.101741. View

18.

Wang Z, Bian H, Wang J, Cheng Z, Wang K, De W . Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011; 104(7):847-51. DOI: 10.1002/jso.22008. View

19.

Zheng Y, Li R, Zhang X, Ren X . Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest. 2013; 31(3):197-205. DOI: 10.3109/07357907.2013.775294. View

20.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View